Global Donepezil market will reach 880 million US$ by the end of 2025 QYRESEARCH FOCUS ON MARKET SURVEY AND RESEARCH
w w w. q y r e s e a r c h . c o m
Contact
Beijing Hengzhou Bozhi International Information Consulting Web: www.qyresearch.com TEL:+86-13660489419 Office:+86-2022093278 Media: press@qyresearch.com Marketing: sales@qyresearchglobal.com Facebook: @QYResearchOfficial Twitter: @QYResearch_ Wechat Official Account: QYResearch Weibo: 恒州博智
w w w. q y r e s e a r c h . c o m
QYResearch
Donepezil is a medication used in the palliative treatment of Alzheimer's disease. Donepezil is used to improve cognition and behavior of people with Alzheimer's, but does not slow the progression of or cure the disease.
Common side effects include loss of appetite, gastrointestinal upset, diarrhea, difficulty sleeping, vomiting, or muscle cramping.
w w w. q y r e s e a r c h . c o m
QYResearch
The classification of Donepezil includes 5mg, 10mg and 23mg, and the proportion of 10mg in 2017 is about 48%. North America is the largest consumption region of Donepezil, with a sales market share nearly 37% in 2017. Europe is the second largest consumption region of Donepezil, enjoying Sales market share nearly 29% in 2017. Donepezil was developed by Eisai and Pfizer and is sold as a generic by multiple suppliers. Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor.
w w w. q y r e s e a r c h . c o m
QYResearch
• The global Donepezil market is valued at 920 million US$ in 2017 and will reach 880 million US$ by the end of 2025, growing at a CAGR of -0.6% during 2018-2025.
Click to view the full report: https://www.qyresearch.com/index/detail/547418/globaldonepezil-market w w w. q y r e s e a r c h . c o m